

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-172) LADEMIRSEN  
PRONUNCIATION lad" e mir' sen  
THERAPEUTIC CLAIM Treatment of kidney fibrosis; Alport Syndrome

CHEMICAL NAME

1. DNA, d(P-thio)([2'-O-(2-methoxyethyl)]rA-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-A-T-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-A-G-T-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-T-G-A-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]U-A-A-G-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-T-[2'-O-(2-methoxyethyl)]rA)

STRUCTURAL FORMULA

acatcagtct gauaagcta

MOLECULAR FORMULA C<sub>201</sub>H<sub>254</sub>N<sub>72</sub>O<sub>101</sub>P<sub>18</sub>S<sub>18</sub>  
MOLECULAR WEIGHT 6429.3 Da  
TRADEMARK None as yet  
SPONSOR Regulus Therapeutics, Inc.  
CODE DESIGNATION RG-012  
CAS REGISTRY NUMBER 1404019-95-9  
UNII KKQ6AQN9LH  
WHO NUMBER 10800

SCS